CMMB.US Chemomab Therapeutics Ltd DRC

Healthcare Biotechnology USA Stocks
1.53 USD
Close of Nov 14, 2026
0.9200 2.99
Market cap
USD 12.3M
P/E
-
P/B
1.31x
ROE
-91.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CMMB.US undervalued?

Graham number

The Graham number of Chemomab Therapeutics Ltd DRC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chemomab Therapeutics Ltd DRC fundamental analysis

No fundamental analysis for Chemomab Therapeutics Ltd DRC yet.

Chemomab Therapeutics Ltd DRC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical t…

Full company profile